Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication
The Food and Drug Administration (FDA) regulates the risks associated with pharmaceutical products; however, some drug uses are not directly regulated, and appropriate usage is left to the physicianâs discretion. These risks can often be ambiguous or uncertain. In this dissertation, I study how cons...
Main Author: | |
---|---|
Other Authors: | |
Format: | Others |
Language: | en |
Published: |
VANDERBILT
2016
|
Subjects: | |
Online Access: | http://etd.library.vanderbilt.edu/available/etd-04042016-131002/ |
id |
ndltd-VANDERBILT-oai-VANDERBILTETD-etd-04042016-131002 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-VANDERBILT-oai-VANDERBILTETD-etd-04042016-1310022016-04-12T05:28:33Z Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication Philip Gentry, Anne Elissa Law and Economics The Food and Drug Administration (FDA) regulates the risks associated with pharmaceutical products; however, some drug uses are not directly regulated, and appropriate usage is left to the physicianâs discretion. These risks can often be ambiguous or uncertain. In this dissertation, I study how consumers respond to ambiguity in pharmaceutical risk. I also examine two areas where risk is either not directly regulated or is perceived to be insufficiently regulatedâI study whether patients, physicians, and third-party payers are sensitive to these risks or whether further regulation would be preferable. This dissertation begins by using an incentivized experiment to empirically estimate participantsâ reactions to ambiguity in risks that a drug is unsafe or ineffective in the presence of framing effects. The experiment finds that attitudes toward ambiguity are sensitive to risk type and framing effects. The dissertation then concentrates on two areas where risk is not directly regulated: The second chapter studies narrow therapeutic index drugs, drugs for which the generic approval process has been suspected to be inadequate in ensuring therapeutic equivalence. It finds evidence of a price penalty for the extra risk associated with NTI drugs. The third chapter studies off-label usesâthe prescription of a drug for an unapproved useâand examines whether inappropriate off-label uses are relinquished even in the absence of direct FDA regulation. It finds evidence that relinquishment of off-label uses can be spurred by False Claims Act suits. The dissertation provides insight into areas in which parties seem sensitive to risk absent regulation and those in which further regulation may be necessary. Dr. Melinda J. Beeuwkes Buntin Dr. W. Kip Viscusi James Blumstein Dr. Daniel Gervais VANDERBILT 2016-04-11 text application/pdf http://etd.library.vanderbilt.edu/available/etd-04042016-131002/ http://etd.library.vanderbilt.edu/available/etd-04042016-131002/ en unrestricted I hereby certify that, if appropriate, I have obtained and attached hereto a written permission statement from the owner(s) of each third party copyrighted matter to be included in my thesis, dissertation, or project report, allowing distribution as specified below. I certify that the version I submitted is the same as that approved by my advisory committee. I hereby grant to Vanderbilt University or its agents the non-exclusive license to archive and make accessible, under the conditions specified below, my thesis, dissertation, or project report in whole or in part in all forms of media, now or hereafter known. I retain all other ownership rights to the copyright of the thesis, dissertation or project report. I also retain the right to use in future works (such as articles or books) all or part of this thesis, dissertation, or project report. |
collection |
NDLTD |
language |
en |
format |
Others
|
sources |
NDLTD |
topic |
Law and Economics |
spellingShingle |
Law and Economics Philip Gentry, Anne Elissa Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication |
description |
The Food and Drug Administration (FDA) regulates the risks associated with pharmaceutical products; however, some drug uses are not directly regulated, and appropriate usage is left to the physicianâs discretion. These risks can often be ambiguous or uncertain. In this dissertation, I study how consumers respond to ambiguity in pharmaceutical risk. I also examine two areas where risk is either not directly regulated or is perceived to be insufficiently regulatedâI study whether patients, physicians, and third-party payers are sensitive to these risks or whether further regulation would be preferable. This dissertation begins by using an incentivized experiment to empirically estimate participantsâ reactions to ambiguity in risks that a drug is unsafe or ineffective in the presence of framing effects. The experiment finds that attitudes toward ambiguity are sensitive to risk type and framing effects. The dissertation then concentrates on two areas where risk is not directly regulated: The second chapter studies narrow therapeutic index drugs, drugs for which the generic approval process has been suspected to be inadequate in ensuring therapeutic equivalence. It finds evidence of a price penalty for the extra risk associated with NTI drugs. The third chapter studies off-label usesâthe prescription of a drug for an unapproved useâand examines whether inappropriate off-label uses are relinquished even in the absence of direct FDA regulation. It finds evidence that relinquishment of off-label uses can be spurred by False Claims Act suits. The dissertation provides insight into areas in which parties seem sensitive to risk absent regulation and those in which further regulation may be necessary. |
author2 |
Dr. Melinda J. Beeuwkes Buntin |
author_facet |
Dr. Melinda J. Beeuwkes Buntin Philip Gentry, Anne Elissa |
author |
Philip Gentry, Anne Elissa |
author_sort |
Philip Gentry, Anne Elissa |
title |
Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication |
title_short |
Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication |
title_full |
Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication |
title_fullStr |
Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication |
title_full_unstemmed |
Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication |
title_sort |
safety and effectiveness: the fdaâs approach to risk in prescription medication |
publisher |
VANDERBILT |
publishDate |
2016 |
url |
http://etd.library.vanderbilt.edu/available/etd-04042016-131002/ |
work_keys_str_mv |
AT philipgentryanneelissa safetyandeffectivenessthefdaasapproachtoriskinprescriptionmedication |
_version_ |
1718222087052591104 |